NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer

The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systematical therapy in patients with ocally advanced pancreatic cancer.

Trial Details

NCT ID
NCT06494514
Phase
NA
Sponsor
Du Juan
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • nal-IRI+Oxaliplatin+5-FU/LV+PD-1
  • Gemcitabine + albumin-paclitaxel+PD-1
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Histologically or cytologically confirmed pancreatic cancer;
  • ECOG performance no more than 2;
  • Radiographically assessed as locally advanced pancreatic cancer according to NCCN guidelines;
  • No previous anti-tumor therapy；

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →